PEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Penumbra Inc (PEN) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company's financial performance is robust and the stock has potential for growth, the lack of significant positive trading signals, neutral sentiment from hedge funds and insiders, and the ongoing merger-related uncertainty suggest holding off on immediate investment.
The MACD is positive and expanding, indicating a potential upward trend. However, the RSI is neutral at 49.875, and moving averages are converging, showing no clear directional momentum. The stock price is near its pivot level of 330.857, with resistance at 332.889 and support at 328.824.
Strong financial performance in Q4 2025, with revenue up 22.14% YoY, net income up 40.55% YoY, and EPS up 46.34% YoY. Gross margin also improved to 68.02%. Additionally, the U.S. Embo growth of 43% reflects strong product traction and sales force expansion.
Merger-related uncertainty as Penumbra is being sold for cash or shares of Boston Scientific, with potential legal challenges. Analysts have lowered the price target from $360 to $345 due to delays in Thunderbolt approval and missed U.S. Thrombectomy targets.
In Q4 2025, Penumbra reported strong growth: Revenue increased to $385.39M (up 22.14% YoY), Net Income rose to $47.34M (up 40.55% YoY), EPS increased to 1.2 (up 46.34% YoY), and Gross Margin improved to 68.02% (up 1.84% YoY).
Evercore ISI maintains an Outperform rating but lowered the price target from $360 to $345 due to delays in Thunderbolt approval and missed U.S. Thrombectomy targets. However, strong U.S. Embo growth offsets some concerns.
